Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00050843 · ClinicalTrials.gov registry record · Phase 3
A Study to Access the Safety/Efficacy of Thalidomide in the Treatment of Anemia in Patients With Myelodysplastic Syndromes
A Phase 3 study, sponsored by Celgene Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 220
- Enrollment target
NCT00050843 is a Phase 3 study that has completed, run by Celgene Corporation. The registered enrollment target is 220 participants.
The verdict
NCT00050843, a Phase 3 study, has completed, sponsored by Celgene Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 220 participants
- Enrollment target
Study Summary
The primary objective of the study is to determine the efficacy of thalidomide for the treatment of anemia in patients with myelodysplastic syndromes (MDS).
Interventions
- DRUG thalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2001-08 |
| Est. Completion | 2004-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00050843
The ClinicalTrials.gov registry entry for NCT00050843 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene Corporation, which has 40 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which thalidomide is the first listed.
NCT00050843 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00050843 about?
NCT00050843 is a clinical study titled "A Study to Access the Safety/Efficacy of Thalidomide in the Treatment of Anemia in Patients With Myelodysplastic Syndromes". The primary objective of the study is to determine the efficacy of thalidomide for the treatment of anemia in patients with myelodysplastic syndromes (MDS).
What is the current status of trial NCT00050843?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 220 participants. The study started on 2001-08. Estimated completion is 2004-02.
What interventions are being tested in trial NCT00050843?
The interventions under investigation include: thalidomide (DRUG).
Who is sponsoring clinical trial NCT00050843?
This trial is sponsored by Celgene Corporation, which has 40 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.